ValuEngine lowered shares of Voyager Therapeutics (NASDAQ:VYGR) from a strong-buy rating to a buy rating in a research note issued to investors on Monday morning.

Several other research firms have also weighed in on VYGR. Canaccord Genuity set a $35.00 target price on Voyager Therapeutics and gave the stock a buy rating in a report on Wednesday, June 6th. BTIG Research reiterated a buy rating and set a $32.00 target price on shares of Voyager Therapeutics in a report on Thursday, June 7th. BidaskClub upgraded Voyager Therapeutics from a hold rating to a buy rating in a report on Wednesday, June 6th. Chardan Capital reiterated a hold rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, June 21st. Finally, HC Wainwright assumed coverage on Voyager Therapeutics in a report on Monday, June 4th. They set a buy rating and a $30.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $31.09.

VYGR stock opened at $18.60 on Monday. The stock has a market cap of $603.63 million, a price-to-earnings ratio of -7.05 and a beta of 2.89. Voyager Therapeutics has a 1-year low of $11.54 and a 1-year high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. equities analysts predict that Voyager Therapeutics will post -3.19 EPS for the current year.

In other news, Director Glenn Pierce purchased 5,000 shares of the company’s stock in a transaction on Wednesday, September 12th. The shares were purchased at an average price of $18.44 per share, with a total value of $92,200.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James A. Geraghty purchased 3,000 shares of the company’s stock in a transaction on Monday, September 10th. The stock was purchased at an average cost of $19.39 per share, for a total transaction of $58,170.00. Following the purchase, the director now directly owns 76,588 shares in the company, valued at $1,485,041.32. The disclosure for this purchase can be found here. Insiders acquired a total of 11,000 shares of company stock worth $205,300 in the last three months. Company insiders own 33.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. Metropolitan Life Insurance Co. NY raised its stake in shares of Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after purchasing an additional 3,157 shares during the period. MetLife Investment Advisors LLC raised its stake in shares of Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after purchasing an additional 2,964 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Voyager Therapeutics in the 1st quarter valued at about $227,000. Thompson Davis & CO. Inc. raised its stake in shares of Voyager Therapeutics by 187.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock valued at $234,000 after purchasing an additional 7,800 shares during the period. Finally, Hershey Trust Co. acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at about $284,000. 89.86% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Further Reading: What strategies should day traders use to execute a trade?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.